ALZN: חוב כולל להון Alzamend

Alzamend Neuro, Inc. (ALZN) faces high clinical risks and funding shortages in the development of Alzheimer's drugs, as evidenced by this price chart illustrating cost trends, where the individual debt-to-equity ratio stands at 0.00. Investors harbor doubts regarding the qualifications of top management and the transparency of intra-holding transactions. Meanwhile, the company ensures the preservation of drug properties through strict adherence to temperature controls during transportation.

During fundamental asset screening, this indicator allows for an assessment of financial stability and the degree of business reliance on borrowed funds. The current D/E ratio (total debt to equity) at 0.00 reflects the proportion of total liabilities to equity, which, for the mission-driven model of Alzamend Neuro (ALZN) with its focus on R&D and equity-based incentives for scientists, signifies a balance between leverage and capital.